Payment overview · 2025
General Payments
$151.02
8 reported records · 4 companies
Healthcare provider profile · identity verified
Michael James Martin, MD.
Allopathic & Osteopathic Physicians|Internal Medicine · MILLERSPORT, OH · NPI 1083662951
Verified facts
What the public records show
CMS Open Payments records show Michael James Martin, MD. received $151.02 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 45.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.36 | 45.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.67 | 30.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.99 | 12.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.00 | 11.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.02 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.36 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.36 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.67 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 675 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 555 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 97 |
| Potassium Chloride | Potassium Chloride | 344 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 336 | 101 |
| Omeprazole | Omeprazole | 327 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 322 | 98 |
| Lisinopril | Lisinopril | 289 | 85 |
| Metformin Hcl | Metformin Hcl | 278 | 77 |
| Furosemide | Furosemide | 238 | 74 |
| Gabapentin | Gabapentin | 237 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 203 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 47 |
| Famotidine | Famotidine | 190 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 188 | 58 |
| Simvastatin | Simvastatin | 180 | 51 |
| Jardiance | Empagliflozin | 177 | 38 |
| Eliquis | Apixaban | 170 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 52 |
| Carvedilol | Carvedilol | 161 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 44 |
| Prednisone | Prednisone | 144 | 97 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 37 |
| Tramadol Hcl | Tramadol Hcl | 125 | 18 |
| Allopurinol | Allopurinol | 124 | 34 |
| Glimepiride | Glimepiride | 119 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 21 |
| Sertraline Hcl | Sertraline Hcl | 117 | 35 |
| Spironolactone | Spironolactone | 116 | 38 |
| Meloxicam | Meloxicam | 112 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 16 |
| Celecoxib | Celecoxib | 100 | 36 |
| Xarelto | Rivaroxaban | 97 | 14 |
| Montelukast Sodium | Montelukast Sodium | 94 | 27 |
| Trazodone Hcl | Trazodone Hcl | 93 | 33 |
| Donepezil Hcl | Donepezil Hcl | 88 | 24 |
| Cephalexin | Cephalexin | 83 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 19 |
| Glipizide Er | Glipizide | 80 | 18 |
| Atenolol | Atenolol | 79 | 22 |
| Ozempic | Semaglutide | 78 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 24 |
| Amoxicillin | Amoxicillin | 64 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 17 |
| Metformin Hcl Er | Metformin Hcl | 59 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 41 |
| Pregabalin | Pregabalin | 58 | 13 |
| Alprazolam | Alprazolam | 57 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 19 |
| Bupropion Xl | Bupropion Hcl | 56 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 28 |
| Fluconazole | Fluconazole | 52 | 28 |
| Buspirone Hcl | Buspirone Hcl | 50 | 12 |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Warfarin Sodium | Warfarin Sodium | 47 | 15 |
| Finasteride | Finasteride | 45 | 15 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 15 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 12 |
| Cefdinir | Cefdinir | 43 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 12 |
| Azithromycin | Azithromycin | 41 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 14 |
| Terazosin Hcl | Terazosin Hcl | 41 | 11 |
| Nystatin | Nystatin | 40 | 27 |
| Lansoprazole | Lansoprazole | 38 | 11 |
| Estradiol | Estradiol | 37 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Klor-Con M10 | Potassium Chloride | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Rybelsus | Semaglutide | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 17 |
| Trimethoprim | Trimethoprim | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | 13 |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.02 · 8 records | ABBVIE INC. | Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error